Drug intelligence / Profile preview

GB-ADS2

Development stage: Preclinical
Lead developer: GlycosBio
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Topical

Overview

GB-ADS2 is a clinical-stage topical drug delivery candidate developed by GlycosBio, utilizing their proprietary Activated Oil System (AOS) technology. This lipid-based delivery platform is engineered to enhance the bioavailability and skin penetration of active ingredients or nutritional lipids. GB-ADS2 is specifically targeted for anti-aging applications, where it aims to optimize the delivery of actives to the skin to achieve therapeutic or cosmeceutical effects. The AOS technology focuses on lipid engineering to improve the transport of molecules that are otherwise difficult to deliver topically, potentially increasing their efficacy in reducing signs of aging.

Beyond the preview

Go deeper on GB-ADS2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GB-ADS2.

Explore the full profile